1M6MYTD1Y5YMAX
Loading quotes...
Forecast
| Buy |
0 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Apr 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -2.78K | 87.43% |
| Net profit | -2.03M | 16.24% |
| EBITDA | -1.44M | 34.87% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €26.08M |
Number of shares | 377.64M |
52-week high/low | €0.13 - €0.0604 |
| Dividends | No |
Beta | 0.64 |
P/E ratio | -3.13 |
PEG ratio | -0.04 |
P/B ratio | -4.01 |
P/S ratio | 0.00 |
Company profile
| Name | Sernova Biotherapeutics |
| CEO | Jonathan N. Rigby |
| Headquarters | Mississauga,
on Canada |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 8 |
Discover assets
Shareholders of Sernova Biotherapeutics also invest in the following assets
